Skip to main content
Quantum Genomics logo

Quantum Genomics — Investor Relations & Filings

Ticker · ALQGC ISIN · FR0011648971 LEI · 969500TFCD8K9RPM9K97 PA Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2021-12-06 Regulatory Filings
Country FR France
Listing PA ALQGC

About Quantum Genomics

https://quantum-genomics.com/

Quantum Genomics is a biopharmaceutical company focused on developing a new class of medications for cardiovascular diseases with high unmet medical needs, such as difficult-to-treat or resistant hypertension and heart failure. The company's core research is based on a breakthrough therapeutic approach involving the inhibition of Brain Aminopeptidase A (BAPA). Its lead drug candidate, firibastat, is a first-in-class BAPA inhibitor designed to offer a novel treatment mechanism for managing these conditions.

Recent filings

Filing Released Lang Actions
Quantum Genomics conclut un accord de licence et de production exclusif avec le laboratoire pharmaceutique JULPHAR
Regulatory Filings Classification · 95% confidence The document text is a press release announcing a significant business event: an exclusive licensing and manufacturing agreement between Quantum Genomics and Julphar concerning the drug firibastat. It details financial terms (upfront payments, milestones, royalties) and geographic scope. This type of announcement, detailing strategic partnerships, licensing deals, or major corporate transactions (like M&A or significant financing commitments, as Julphar is also investing), typically falls under corporate actions or strategic updates. Since there is no specific category for 'Licensing Agreement,' the closest fit among the provided options that captures a major strategic business development involving financing/partnership is 'Capital/Financing Update' (CAP) due to the explicit mention of investment/placement, or potentially 'Regulatory Filings' (RNS) if it were a mandatory disclosure not covered elsewhere. However, given the content is a detailed announcement of a strategic deal involving future revenue streams and an equity investment, 'CAP' is a strong candidate, but 'RNS' (Regulatory Filings/General Announcement) is often used for press releases detailing such non-standard material events. Since the document is a detailed press release announcing a major commercial and financial agreement, and not a standard financial report (10-K, IR, ER), it is best classified as a general regulatory announcement or strategic update. Given the options, and the nature of the announcement being a material event disclosure, 'RNS' (Regulatory Filings) serves as the most appropriate general category for significant, non-standard corporate news releases that aren't strictly about earnings or board changes. It is not a Call Transcript (CT), Earnings Release (ER), or a formal statutory report.
2021-12-06 French
Quantum Genomics signs an exclusive license and production agreement with Gulf Pharmaceuticals Industries Julphar.
Capital/Financing Update Classification · 95% confidence The document announces a significant business event: Quantum Genomics signing an exclusive license and production agreement with Julphar for the drug firibastat, including financial terms (up to $20M in milestones and royalties) and a private placement investment by Julphar. This type of announcement details a major corporate transaction, partnership, or financing activity. It is not a standard periodic financial report (10-K, IR, ER), nor is it a management discussion (MDA) or an investor presentation (IP). It most closely aligns with a Capital/Financing Update (CAP) due to the explicit mention of milestone payments, royalties, and a private placement investment, which are all capital/financing structure elements. Since it is a press release format announcing a strategic deal involving financing elements, CAP is the most appropriate fit over the general Regulatory Filings (RNS).
2021-12-06 English
Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.
Regulatory Filings Classification · 96% confidence The document announces a specific corporate event: Quantum Genomics signing an exclusive license agreement with Teva Israel Ltd. regarding the drug firibastat. This involves a strategic partnership, licensing terms (payments and royalties), and executive commentary. This type of announcement, detailing a significant business transaction or agreement that impacts the company's operations or future revenue streams, is best classified as a general corporate announcement. Since there is no specific category for 'Licensing Agreement' or 'M&A Activity' (TAR is for Mergers/Takeovers), and it is not a standard financial report (10-K, IR, ER), it falls under the general regulatory/corporate announcement category. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for significant, non-standard corporate news that is typically disclosed via regulatory channels when a more specific code is unavailable.
2021-11-25 English
Quantum Genomics conclut un accord de licence exclusif avec Teva Israel Ltd.
Regulatory Filings Classification · 92% confidence The document announces a specific corporate event: the signing of an exclusive licensing agreement between Quantum Genomics and Teva Israel Ltd. for the commercialization of the drug firibastat in Israel. This type of announcement details a significant business transaction, including financial terms (up to $11M plus royalties) and strategic partnership details. This does not fit the definitions for standard periodic reports (10-K, IR, ER), management changes (MANG), or shareholder votes (AGM-R, DVA). It is a material corporate event announcement. Since there is no specific category for 'Licensing Agreement' or 'M&A Activity' (TAR is for mergers/takeovers), and it is a significant business development, it most closely aligns with a general regulatory announcement or a significant corporate action announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a material, non-standard announcement, although 'Capital/Financing Update' (CAP) is sometimes used for major deals, this is primarily a licensing/commercialization deal, not direct financing. However, looking closely at the definitions, none perfectly capture a licensing deal. Since it is a major business development announcement that is not a standard financial report, 'RNS' (Regulatory Filings) serves as the best general category for material, non-standard corporate news.
2021-11-25 French
Dr. Catherine Llorens-Cortes receives the 2021 Emilia Valori Prize from the French Academy of Sciences
Regulatory Filings Classification · 100% confidence The document is a press release announcing that Dr. Catherine Llorens-Cortes received the 2021 Emilia Valori Prize from the French Academy of Sciences for her research related to Quantum Genomics' drug development platform. This announcement concerns an award received by a key figure/researcher associated with the company, which falls under general corporate news or management/personnel recognition, but it is not a standard regulatory filing like 10-K, ER, or IR. It is not a management change (MANG), a director's dealing (DIRS), or a specific financial event (CAP, DIV, SHA). Since it is a specific announcement of an award/recognition that doesn't fit the highly specific categories like AGM-R, 10-K, ER, or CT, the most appropriate classification is the general regulatory/corporate announcement fallback category, RNS (Regulatory Filings), as it is a formal communication to the market about a significant, non-financial event.
2021-11-23 English
Dr. Catherine Llorens-Cortès reçoit le prix Emilia Valori 2021 décerné par l'Académie des Sciences
Regulatory Filings Classification · 100% confidence The document is a press release from Quantum Genomics announcing that Dr. Catherine Llorens-Cortès received the Emilia Valori 2021 Prize from the French Academy of Sciences for her research work. This type of announcement, detailing an award or recognition given to a key person (like a director or researcher) within the company, does not fit the specific categories like 10-K, ER, or IR. It is related to personnel/management achievements but is not a change in the board (MANG) or remuneration (DEF 14A). Since it is a specific, non-standard announcement that doesn't fit the primary financial reporting or corporate action codes, the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous official announcements not covered elsewhere.
2021-11-23 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.